AbbVie Announces UK Pricing Strategy for ELAHERE® (mirvetuximab soravtansine-gynx)

AbbVie Announces UK Pricing Strategy for ELAHERE® (mirvetuximab soravtansine-gynx)

  • The list price will be consistent with the United States to reflect the value of the innovation
  • AbbVie is committed to ensuring that developed nations fully…

Continue Reading